BETA: Please send your feedback!
CA
CA:NAS
Packaged Software
—
LARGE cap
(—)
—
since start of 2019
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 1
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1993
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
website
Headquarters
Executives
| Name | Title | Gender |
| Michael P. Gregoire | Chief Executive Officer & Director | Male |
| Arthur Frederic Weinbach, CPA | Non-Executive Chairman | Male |
| Charles B. Wang | Founder | Male |
| Russell M. Artzt | Founder | Male |
| Traci T. Tsuchiguchi | Vice President-Investor Relations | Female |
| Michael C. Bisignano | Secretary & General Counsel | Male |
| Otto Berkes | Chief Technology Officer | Male |
| Kieran J. McGrath | Chief Financial Officer & Executive Vice President | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 1
TG Therapeutics - Competitors and Related Companies
How TG Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
TG Therapeutics
TGTX:NAS
Biotechnology
$569.95mm
SMALL cap
$6.01
(-0.28%)
0.42%
since start of 2019
-3.12
Loading…